- Home
- SHOT vs ALVR Comparison
SHOT vs ALVR Comparison
Compare SHOT & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- ALVR
- Stock Information
- Founded
- SHOT 2018
- ALVR 2013
- Country
- SHOT United States
- ALVR United States
- Employees
- SHOT N/A
- ALVR N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHOT Health Care
- ALVR Health Care
- Exchange
- SHOT Nasdaq
- ALVR Nasdaq
- Market Cap
- SHOT 62.8M
- ALVR 52.2M
- IPO Year
- SHOT 2020
- ALVR 2020
- Fundamental
- Price
- SHOT $0.74
- ALVR $0.45
- Analyst Decision
- SHOT
- ALVR Sell
- Analyst Count
- SHOT 0
- ALVR 5
- Target Price
- SHOT N/A
- ALVR $1.00
- AVG Volume (30 Days)
- SHOT 914.3K
- ALVR 344.3K
- Earning Date
- SHOT 11-14-2024
- ALVR 11-12-2024
- Dividend Yield
- SHOT N/A
- ALVR N/A
- EPS Growth
- SHOT N/A
- ALVR N/A
- EPS
- SHOT N/A
- ALVR N/A
- Revenue
- SHOT $652,495.00
- ALVR N/A
- Revenue This Year
- SHOT N/A
- ALVR N/A
- Revenue Next Year
- SHOT N/A
- ALVR N/A
- P/E Ratio
- SHOT N/A
- ALVR N/A
- Revenue Growth
- SHOT 68.01
- ALVR N/A
- 52 Week Low
- SHOT $0.55
- ALVR $0.40
- 52 Week High
- SHOT $5.12
- ALVR $2.45
- Technical
- Relative Strength Index (RSI)
- SHOT 31.75
- ALVR 31.87
- Support Level
- SHOT $0.73
- ALVR $0.40
- Resistance Level
- SHOT $1.03
- ALVR $0.53
- Average True Range (ATR)
- SHOT 0.09
- ALVR 0.04
- MACD
- SHOT -0.01
- ALVR 0.00
- Stochastic Oscillator
- SHOT 5.91
- ALVR 27.34
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.